Clinical trials: CAD
Coronary Artery Stenosis
Angiography Study of BioNIR Drug Eluting Stent System (NIREUS)
The NIREUS study aims to demonstrate angiographic non-inferiority for the BioNIR Ridaforolimus Eluting Coronary Stent System (hereafter referred to as BioNIR) in comparison to the Resolute zotarolimus-eluting stent (hereafter…
- Trial name
- NIREUS (NCT01995500)
- Testing
- BioNIR, Resolute
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Medinol Ltd.
Coronary Stenosis, Coronary Disease
BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) in Coronary Stenosis Trial
Device: EluNIR Ridaforolimus Eluting Coronary Stent System - (hereafter referred to as EluNIR) 2.25 mm diameter (8 mm, 12 mm, 15 mm, 17 mm, 20 mm, 24 mm, 28 mm and 33 mm length) Objectives: To further assess the safety and…
- Conditions
- Coronary Stenosis, Coronary Disease, Myocardial Ischemia, Cardiovascular Diseases
- Trial name
- NCT04761939
- Testing
- EluNIR Ridaforolimus Eluting Coronary Stent System
- Where
- 9 sites in Israel
- Volunteers
- 81 people
- Sponsor
- Medinol Ltd.
Coronary Artery Disease
Multicenter Study to Evaluate the Procedural Safety and Efficacy of ELCA in CAD
This is a Prospective, Open label, Non-randomized, Single-Arm, Multicenter Study to Evaluate the Procedural Safety and Efficacy of ELCA® in Treatment of Patients with Single or Multivessel Coronary Artery Disease (CAD).
- Trial name
- ELCA-CAD (NCT03284229)
- Testing
- Excimer Laser Coronary Atherectomy
- Where
- 5 sites in India
- Volunteers
- 28 people
- Sponsor
- Spectranetics Corporation
Acute ST Segment Elevation Myocardial Infarction
Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
The goal of the study was to evaluate the effect of single administration of RPH-104 at 80 mg and 160 mg on parameters of systemic inflammation and outcomes of the disease in subjects with ST-segment elevation myocardial…
- Trial name
- NCT04463251
- Testing
- RPH-104 80 mg
- Where
- 11 sites in United States, Russia
- Volunteers
- 102 people
- Sponsor
- R-Pharm Overseas, Inc.
Coronary Artery Disease
Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Participants being evaluated for suspected or known Coronary artery Disease (CAD) based on signs and/or symptoms, will be invited to participate in the study.
- Trial name
- GadaCAD 1 (NCT01890421)
- Testing
- Gadobutrol (Gadovist, Gadavist, BAY86-4875)
- Where
- 23 sites in United States, France and 5 more
- Volunteers
- 426 people
- Sponsor
- Bayer
Coronary Heart Disease
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP
This Phase 2a clinical trial evaluated the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, to reduce key markers of inflammation related to CVD…
- Trial name
- NCT06031844
- Testing
- DFV890
- Where
- 7 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Diseases
Study of Management Alterations Resulting From CaRi-Heart® Technology in Patients Undergoing Coronary Computed Tomography Angiography (CCTA) for the Evaluation of Coronary Artery Disease: A United States Based Multi-Centre Study (SMART-CCTA-1)
This study is an assessment of the impact of CaRi-Heart® on the clinical management of patients across at least three centres in the USA.
- Trial name
- SMART-CCTA-1 (NCT06986733)
- Volunteers
- 300 people
- Sponsor
- Caristo Diagnostics Limited
Chronic Coronary Syndrome, Coronary Artery Disease
Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary Plaque
The primary objective of this study is to assess the accuracy in terms of sensitivity, specificity, negative and positive predicted values of the DL-based algorithm with respect to correct identification of the plaque and…
- Conditions
- Chronic Coronary Syndrome, Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome
- Trial name
- FOCUS DL (NCT06186336)
- Testing
- Deep Learning-based Vulnerable Plaque Detection and Assessment Tool
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- GE Healthcare
Coronary Artery Disease (CAD)
Coroflex ISAR 2000 Extended Registry (ISAR2000 Extended)
Postmarket surveillance in terms of the safety and efficacy of Sirolimus-eluting Coroflex ISAR Stent for the treatment of "real world" patients with de-novo and restenotic lesions after stand-alone angioplasty in coronary…
- Trial name
- NCT02905214
- Testing
- stenting with the Coroflex ISAR sirolimus-eluting stent
- Where
- 3 sites in Germany, Malaysia and 1 more
- Volunteers
- 4,369 people
- Sponsor
- B. Braun Melsungen AG
Coronary Artery Disease
Assessing Diagnostic Value of Non-invasive FFR-CT in Coronary Care in the Emergency Department
This is a prospective multi-center study. All clinically stable, symptomatic patients who present to the emergency department (ED) or observation unit with suspected coronary artery disease (CAD) and who have at least one ≥40%…
- Trial name
- ADVANCE-ED (NCT05325112)
- Testing
- FFR-CT
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- HeartFlow, Inc.
Coronary Artery Disease
Non-inferiority Clinical Trial to Compare the Safety and Performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions
This is a prospective, open-label, multicentre, randomized, non-inferiority clinical trial to compare the safety and performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System versus Contemporary…
- Trial name
- MeRethonRCT (NCT05417893)
- Testing
- MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)
- Sponsor
- Meril Life Sciences Pvt. Ltd.
Coronary Artery Disease, Myocardial Ischemia
AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population
Prospective, Randomized (2:1), active control, single-blind, non-inferiority, multicenter, Japanese Clinical Trial to evaluate the safety and effectiveness of Absorb™ BVS (AVJ-301) in the treatment of subjects with ischemic heart…
- Trial name
- ABSORB JAPAN (NCT01844284)
- Testing
- XIENCE PRIME®/XIENCE Xpedition™, Absorb™ BVS
- Where
- 39 sites in Japan
- Volunteers
- 400 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter
The objective of the PINNACLE I Clinical Study is to assess safety and performance of the LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX) to treat moderately to severely…
- Trial name
- PINNACLE-I (NCT05828173)
- Testing
- LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX)
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 60 people
- Sponsor
- Elixir Medical Corporation
Cardiovascular Disease, de Novo Coronary Lesions
TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program
The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical…
- Trial name
- ARRIVE 2 (NCT00569751)
- Testing
- TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System
- Where
- 53 sites in United States
- Volunteers
- 5,016 people
- Sponsor
- Boston Scientific Corporation
Primary Hypercholesterolemia
Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting
This study assessed the safety and efficacy of generic Rosuvastatin in reducing plasma low density lipoprotein (LDL) cholesterol in Lebanese adult patients (18 years or older) with dyslipidemia for both primary and secondary…
- Trial name
- NCT03516955
- Testing
- Rosuvastatin
- Volunteers
- 317 people
- Sponsor
- Hikma Pharmaceuticals LLC
Coronary Artery Disease, Everolimus
SPIRIT FIRST Clinical Trial of the Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System
Prospective, randomized, controlled, single-blinded, parallel two-arm, multicenter trial. Test arm: XIENCE V® Everolimus Eluting Coronary Stent System(stent length: 18mm, diameter: 3.0mm) Control arm: Metallic stent (MULTI-LINK…
- Conditions
- Coronary Artery Disease, Everolimus, Vascular Disease, Myocardial Ischemia
- Trial name
- NCT00180453
- Testing
- Coronary artery drug eluting stent placement, Coronary artery stent placement
- Where
- 7 sites in Denmark, Germany and 1 more
- Volunteers
- 60 people
- Sponsor
- Abbott Medical Devices
Coronary Heart Disease
Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)
The purpose of this study is to determine: (1) the safety and pharmacokinetics of APL180 administered as a single intravenous infusion in healthy volunteers, and (2) the safety, pharmacokinetics and pharmacodynamics of single and…
- Trial name
- NCT00568594
- Testing
- APL180
- Where
- 11 sites in United States, Belgium and 5 more
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Novartis
Percutaneous Coronary Intervention, Coronary Artery Disease (CAD)
Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)
The study investigates the safety and efficacy of PMX-60056 for the Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)
- Conditions
- Percutaneous Coronary Intervention, Coronary Artery Disease (CAD), Angioplasty
- Trial name
- NCT01312935
- Testing
- PMX-60056
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- PolyMedix, Inc.
Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
The aim of this study is to establish the diagnostic performance of the AngioAI+ System (AngioInsight, Inc, USA) for estimating: 1. Fractional flow reserve (FFR) and 2.
- Trial name
- SMARTFLOW (NCT07676097)
- Testing
- Patients with intermediate coronary artery stenosis with clinically indicated FFR assessment., Microvascular assessment
- Where
- 9 sites in United States
- Volunteers
- 620 people
- Sponsor
- AngioInsight
Angina
Double Blind Atorvastatin Amlodipine Study
To evaluate and compare the safety and efficacy of amlodipine, atorvastatin and the combination in patients with symptomatic myocardial ischemia.
- Trial name
- DUAAL (NCT00159718)
- Testing
- amlodipine, atorvastatin
- Where
- 33 sites in Croatia, Czechia and 9 more
- Volunteers
- 360 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.